Skip to content

FOCL

EDAP TMS SA

NASDAQ · Healthcare · Medical - Specialties · FR

$4.07
−0.49%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
—
EPS
—
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
-6.8%
EBITDA
+37.9%
EPS
+31.1%

Three-year CAGR

Revenue
+6.9%
EBITDA
-41.5%
EBIT
-9.8%
Net income
-42.6%
EPS
-41.8%
Free cash flow
-32.8%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026